Loading...
Loading...
BioClinica
BIOC today announced the immediate
availability of new and expanded imaging services critical for clinical
trials in the area of osteoarthritis (OA), a disease affecting over 21
million people in the United States.
Colin G. Miller PhD FICR CSci, Senior Vice President of Medical Affairs,
commented “BioClinica has been actively involved in the OA Imaging field
for both Disease Modifying Osteoarthritis Drugs (DMOADs) and cartilage
repair for years. We have amassed a thorough understanding of the FDA
requirements and the challenges for these clinical trials. A new
proprietary BioClinica positioning device was specifically developed to
provide highly reproducible radiographs of subjects' knees and
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in